The fibrinolytic system in newborns and children

Clinical Laboratory

Volumn 52, Issue 3-4, 2006, Pages 115-124

  Parmar, Nagina ^a   Albisetti, Manuela ^b   Berry, Leslie R ^c   Chan, Anthony K C ^a,c,d  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^c HENDERSON RESEARCH CENTRE   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

2 antiplasmin ( 2 AP); Fibrinolysis; Heparin; Plasmin; Plasminogen; Plasminogen activator inhibitor (PAI); Therapy; Thromboembolism (TE); Tissue plasminogen activator (tPA); Urokinase plasminogen activator (uPA)

Indexed keywords

ALPHA 2 ANTIPLASMIN; ALPHA 2 MACROGLOBULIN; ALTEPLASE; ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; STREPTOKINASE; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

BLOOD CLOTTING DISORDER; BRAIN HEMORRHAGE; CHILD; CHILD HEALTH CARE; CHILDHOOD; CHILDHOOD DISEASE; CLINICAL FEATURE; DOSE TIME EFFECT RELATION; DRUG FATALITY; FIBRIN CLOT; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; GASTROINTESTINAL HEMORRHAGE; GENETIC DISORDER; HUMAN; LUNG EMBOLISM; LUNG HEMORRHAGE; NEWBORN; NEWBORN DISEASE; NEWBORN PERIOD; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; REFERENCE VALUE; REVIEW; THROMBOEMBOLISM;

ADOLESCENT; ADULT; BLOOD COAGULATION FACTORS; CHILD; CHILD, PRESCHOOL; FEMALE; FIBRINOLYSIS; HUMANS; INFANT; INFANT, NEWBORN; MALE; SERINE ENDOPEPTIDASES; THROMBOLYTIC THERAPY;

EID: 33645570655     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (90)

1. Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991;78:3114-24.
2. Astrup T. The biological significance of fibrinolysis. Lancet 1956; 271:565-8.
3. Carlson MD, Leber S, Deveikis J, Silverstein FS. Successful use of rt-PA in pediatric stroke. Neurology 2001;57:157-8.
4. Pinacho A, Paramo JA, Ezcurdia M, Rocha E. Evaluation of the fibrinolytic system in full-term neonates. Int J Clin Lab Res 1995; 25:149-52.
5. Raum D, Marcus D, Alper CA, Levey R, Taylor PD, Starzl TE. Synthesis of human plasminogen by the liver. Science 1980; 208:1036-7.
6. Robbins KC, Summaria L, Hsieh B, Shah RJ. The peptide chains of human plasmin. Mechanism of activation of human plasminogen to plasmin. J. Biol. Chem. 1967;242:2333-42.
7. Saksela O, Vihko KK. Local synthesis of plasminogen by the seminiferous tubules of the testis. FEBS Lett. 1986;204:193-7.
8. Corrigan JJ, Jr. Neonatal thrombosis and the thrombolytic system: pathophysiology and therapy. Am. J. Pediatr. Hematol. Oncol. 1988; 10:83-91.
9. Suarez CR, Walenga J, Mangogna LC, Fareed J. Neonatal and maternal fibrinolysis: activation at time of birth. Am. J. Hematol. 1985;19:365-72.
10. Peters M, ten Cate JW, Jansen E, Breederveld C. Coagulation and fibrinolytic factors in the first week of life in healthy infants. J. Pediatr. 1985;106:292-5.
11. Clemmensen I, Petersen LC, Kluft C. Purification and characterization of a novel, oligomeric, plasminogen kringle 4 binding protein from human plasma: tetranectin. Eur J Biochem 1986; 156:327-33.
12. Ekelund H, Finnstrom O. The fibrinolytic system in infants of low birth weight and-or short gestational period. Acta Paediatr. Scand. Suppl 1970;206:Suppl.
13. Ekelund H, Finnstrom O. Fibrin degradation products and plasminogen in newborn infants with respiratory disturbances and postnatal asphyxia. Acta Paediatr. Scand. 1972;61:661-9.
14. Estelles A, Aznar J, Gilabert J, Parrilla JJ. Dysfunctional plasminogen in full-term newborn. Pediatr. Res. 1980;14:1180-5.
15. Benavent A, Estelles A, Aznar J, Martinez-Sales V, Gilabert J, Fornas E. Dysfunctional plasminogen in full term newborn-study of active site of plasmin. Thromb. Haemost. 1984;51:67-70.
16. Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen DM et al. Development of the human coagulation system in the full-term infant. Blood 1987;70:165-72.
17. Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen DM et al. Development of the human coagulation system in the healthy premature infant. Blood 1988;72:1651-7.
18. Andrew M, Paes B, Johnston M. Development of the hemostatic system in the neonate and young infant. Am. J. Pediatr. Hematol. Oncol. 1990;12:95-104.
19. Ambrus CM, Ambrus JL, Choi TS, Jung O, Mirand EA, Bart-fay-Szabo A. The fibrinolysin system and its relationship to disease in the newborn. Am. J. Pediatr. Hematol. Oncol. 1979;1:251-60.
20. Corrigan JJ, Jr., Sleeth JJ, Jeter M, Lox CD. Newborn's fibrino-lytic mechanism: components and plasmin generation. Am. J. Hematol. 1989;32:273-8.
21. Edelberg JM, Enghild JJ, Pizzo SV, Gonzalez-Gronow M. Neonatal plasminogen displays altered cell surface binding and activation kinetics. Correlation with increased glycosylation of the protein. J. Clin. Invest 1990;86:107-12.
22. Pennica D, Holmes WE, Kohr WJ, Harkins RN, Vehar GA, Ward CA et al. Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature 1983;301:214-21.
23. Norrman B, Wallen P, Ranby M. Fibrinolysis mediated by tissue plasminogen activator. Disclosure of a kinetic transition. Eur J Biochem 1985;149:193-200.
24. Astedt B, Lindoff C. Plasminogen activators and plasminogen activator inhibitors in plasma of premature and term newborns. Acta Paediatr. 1997;86:111-3.
25. Corti A, Nolli ML, Soffientini A, Cassani G. Purification and characterization of single-chain urokinase-type plasminogen activator (pro-urokinase) from human A431 cells. Thromb. Haemost. 1986; 56:219-24.
26. Lijnen HR, Bachmann F, Collen D, Ellis V, Pannekoek H, Rij-ken DC et al. Mechanisms of plasminogen activation. J. Intern. Med. 1994;236:415-24.
27. Andrew M. The hemostatic system in the infant. In: Nathan DG OF, editor. Hematology of Infancy and Childhood. Philadelphia: W.B. Saunders Company; 1993. p. 115-53.
28. Reverdiau-Moalic P, Gruel Y, Delahousse B, Rupin A, Huart MC, Body G et al. Comparative study of the fibrinolytic system in human fetuses and in pregnant women. Thromb. Res. 1991;61:489-99.
29. Koh SC, Cheong YC, Arulkumaran S, Ratnam SS. Coagulation activation, fibrinolysis and inhibitors in neonates. Ann. Acad. Med. Singapore 1997;26:767-71.
30. Zeitler P, Schuster V. Plasma values for u-PA in children. Eur. J. Pediatr. 1999;158 Suppl 3:S205-S208.
31. Kruithof EK, Tran-Thang C, Ransijn A. Bachmann F. Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood 1984;64:907-13.
32. Madison EL, Goldsmith EJ, Gerard RD, Gething MJ, Sambrook JF. Serpin-resistant mutants of human tissue-type plasminogen activator. Nature 1989;339:721-4.
33. Dosne AM, Dupuy E, Bodevin E. Production of a fibrinolytic inhibitor by cultured endothelial cells derived from human umbilical vein. Thromb. Res. 1978;12:377-87.
34. Emeis JJ, van Hinsbergh VW, Verheijen JH, Wijngaards G. Inhibition of tissue-type plasminogen activator by conditioned medium from cultured human and porcine vascular endothelial cells. Biochem. Biophys. Res. Commun. 1983;110:392-8.
35. Loskutoff DJ, van Mourik JA, Erickson LA, Lawrence D. Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells. Proc. Natl. Acad. Sci. U.S.A. 1983;80:2956-60.
36. Philips M, Juul AG, Thorsen S. Human endothelial cells produce a plasminogen activator inhibitor and a tissue-type plasminogen activator-inhibitor complex. Biochim. Biophys Acta 1984;802:99-110.
37. Dobrovolsky AB, Titaeva EV. The fibrinolysis system: regulation of activity and physiologic functions of its main components. Biochemistry (Mosc.) 2002;67:99-108.
38. Astedt B. Does estrogen replacement therapy predispose to thrombosis? Acta Obstet. Gynecol. Scand. Suppl. 1985;130:71-4.
39. Lecander I, Astedt B. Isolation of a new specific plasminogen activator inhibitor from pregnancy plasma. Br. J. Haematol. 1986;62:221-8.
40. Christensen U, Sottrup-Jensen L. Mechanism of alpha 2-macroglobulin-proteinase interactions. Biochemistry 1984;23:6619-26.
41. Collen D. On the regulation and control of fibrinolysis. Edward Kowalski. Thromb. Haemost. 1980;43:77-89.
42. Aoki N. Natural inhibitors of fibrinolysis. Prog. Cardiovasc. Dis. 1979;21:267-86.
43. Wiman B, Collen D. On the mechanism of the reaction between human alpha 2-antiplasmin and plasmin. J. Biol. Chem. 1979;254: 9291-7.
44. Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen DM et al. Development of the human coagulation system in the full-term infant. Blood 1987;70:165-72.
45. Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell L. Maturation of the hemostatic system during childhood. Blood 1992; 80:1998-2005.
46. Ries M, Easton RL, Longstaff C, Zenker M, Morris HR, Dell A et al. Differences between neonates and adults in carbohydrate sequences and reaction kinetics of plasmin and alpha(2)-anti-plasmin. Thromb. Res. 2002;105:247-56.
47. Bouma BN, Marx PF, Mosnier LO, Meijers JC. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypep-tidase B, procarboxypeptidase R, procarboxypeptidase U). Thromb. Res. 2001;101:329-54.
48. Eaton DL, Malloy BE, Tsai SP, Henzel W, Drayna D. Isolation, molecular cloning, and partial charcterization of a novel carboxypeptidase B from human plasma. J. Biol. Chem. 1991;266:21833-8.
49. Knoefler R, Ludwig K, Kostka H, Kuhlisch E, Siegert G, Suttorp M. The impact of single nucleotide polymorphisms of the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI antigen levels in healthy children and pediatric oncology patients. Semin. Thromb. Hemost. 2003;29:575-83.
50. Barrett AJ. Alpha 2-macroglobulin. Methods Enzymol. 1981;80 Pt C:737-54.
51. Becker CG, Harpel PC. alpha2-Macroglobulin on human vascular endothelium. J. Exp. Med. 1976;144:1-9.
52. Jenner L, Husted L, Thirup S, Sottrup-Jensen L, Nyborg J. Crytal structure of the receptor-binding domain of alpha 2-macroglobulin. Structure. 1998;6:595-604.
53. Valnickova Z. Thogersen IB, Christensen S, Chu CT, Pizzo SV, Enghild JJ. Activated human plasma carboxypeptidase B is re-tained in the blood by binding to alpha2-macroglobulin and pregnancy zone protein. J. Biol. Chem. 1996;271:12937-43.
54. Ling X, Delorme M, Berry L, Ofosu F, Mitchell L, Paes B et al. alpha 2-Macroglobulin remains as important as antithrombin III for thrombin regulation in cord plasma in the presence of endothelial cell surfaces. Pediatr. Res. 1995;37:373-8.
55. Prowse CV, Farrugia A, Boulton FE, Tucker J, Ludlam CA, McLaren M et al. A comparative study using immunological and biological assay of the haemostatic responses to DDAVP infusion venous occlusion and exercise in normal men. Thromb. Haemost. 1984;51:110-4.
56. Monagle P, Chan AK, Albisetti M, Vegh P, Andrew M, Mitchell L. Fibrinolytic system in adolescents: response to venous occlusion stress tests. Pediatr. Res. 2003;53:333-7.
57. Heller C, Becker S, Scharrer I, Kreuz W. Prothrombotic risk factors in childhood stroke and venous thrombosis. Eur. J. Pediatr. 1999;158 Suppl 3:S117-S121.
58. Ehrenforth S, Junker R, Koch HG, Kreuz W, Munchow N, Scharrer I et al. Multicentre evaluation of combined prothrombotic defects associated with thrombophilia in childhood. Childhood Thrombophilia Study Group. Eur. J. Pediatr. 1999;158 Suppl 3:S97-104.
59. Bonduel M, Sciuccati G, Hepner M, Torres AF, Pieroni G, Frontroth JP. Prethrombotic disorders in children with arterial ischemic stroke and sinovenous thrombosis. Arch. Neurol. 1999;56:967-71.
60. Schuster V, Mingers AM, Seidenspinner S, Nussgens Z, Pukrop T, Kreth HW. Homozygous mutations in the plasminogen gene of two unrelated girls with ligneous conjunctivitis. Blood 1997;90:958-66.
61. Schuster V, Seidenspinner S, Muller C, Rempen A. Prenatal diagnosis in a family with severe type I plasminogen deficiency, ligneous conjunctivitis and congenital hydrocephalus. Prenat. Diagn. 1999;19:483-7.
62. Fay WP, Parker AC, Condrey LR, Shapiro AD. Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene. Blood 1997; 90:204-8.
63. Minowa H, Takahashi Y, Tanaka T, Naganuma K, Ida S, Maki I et al. Four cases of bleeding diathesis in children due to congenital plasminogen activator inhibitor-1 deficiency. Haemostasis 1999;29: 286-91.
64. Yoshioka A, Kamitsuji H, Takase T, Iida Y, Tsukada S. Mikami S et al. Congenital deficiency of alpha 2-plasmin inhibitor in three sisters. Haemostasis 1982;11:176-84.
65. Devaussuzenet VM, Ducou-le-Pointe HA, Doco AM, Mary PM, Montagne JR, Favier R. A case of intramedullary haematoma associated with congenital alpha2- plasmin inhibitor deficiency. Pediatr. Radiol. 1998;28:978-80.
66. Sakai M, Asayama K, Otabe T, Kohri T, Shirahata A. Low tissue plasminogen activator relative to plasminogen activator inhibitor-1 as a marker of cardiac complication in children with Kawasaki disease. Clin. Appl. Thromb. Hemost. 2001;7:214-8.
67. Menzel D, Levi M, Dooijewaard C, Peters M, ten Cate JW. Impaired fibrinolysis in the hemolyticuremic syndrome of childhood. Ann. Hematol. 1994;68:43-8.
68. Proesmans W. The role of coagulation and fibrinolysis in the pathogenesis of diarrhea-associated hemolytic uremic syndrome. Semin. Thromb. Hemost. 2001;27:201-5.
69. Weber P, Husemann S, Vielhaber H, Zimmer KP, Nowak-Gottl U. Coagulation and fibrinolysis in children, adolescents, and young adults with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 1999;28:418-22.
70. Green J, Doughty L, Kaplan SS, Sasser H, Carcillo JA. The tissue factor and plasminogen activator inhibitor type-1 response in pediatric sepsis-induced multiple organ failure. Thromb. Haemost. 2002; 87:218-23.
71. Sugiura Y, Ma L, Sun B, Shimada H, Laug WE, Seeger RC et al. The plasminogen-plasminogen activator (PA) system in neuroblastoma: role of PA inhibitor-1 in metastasis. Cancer Res. 1999;59:1327-36.
72. Nsiri B, Gritli N, Bayoudh F, Messaoud T, Fattoum S, Machghoul S. Abnormalities of coagulation and fibrinolysis in homozygous sickle cell disease. Hematol. Cell Ther. 1996;38:279-84.
73. Nsiri B, Gritli N, Mazigh C, Ghazouani E, Fattoum S, Machghoul S. Fibrinolytic response to venous occlusion in patients with homozygous sickle cell disease. Hematol. Cell Ther. 1997; 39:229-32.
74. Yurdakok M, Korkmaz A, Kirazli S, Aygun C, Yigit S. Global fibrinolytic capacity in early respiratory distress syndrome: a pilot study. Am. J. Hematol. 2002;69:255-7.
75. Brus F, Oetomo SB, Schieving J, Groothuis E, Okken A, van Oeveren W. Increased tissue-type plasminogen activator antigen release is not accompanied by increased systemic fibrinolytic activity in severe neonatal respiratory distress syndrome. Pediatr. Res. 1999;45:588-94.
76. Isacson S. Effect of prednisolone on the coagulation and fibrinolytic systems. Scand. J. Haematol. 1970;7:212-6.
77. Ozsoylu S, Strauss HS, Diamon LK. Effects of corticosteroids on coagulation of the blood. Nature 1962;195:1214-5.
78. Jorgensen KA, Sorensen P, Freund L. Effect of glucocorticosteroids on some coagulation tests. Acta Haematol. 1982;68:39-42.
79. Ueda N. Effect of corticosteroids on some hemostatic parameters in children with minimal change nephrotic syndrome. Nephron 1990; 56:374-8.
80. Sutor AH, Niemeyer C, Sauter S, Witt I, Kaufmehl K, Rombach A et al. Changes in blood coagulation in treatment with ALL-BFM-90 and NHL-BFM-90 protocols. Klin. Pediatr. 1992;204:264-73.
81. Gallistl S, Mangge H, Neuwirth G, Muntean W. Activation of the haemostatic system in children with juvenile rheumatoid arthritis correlates with disease activity. Thromb. Res. 1998;92:267-72.
82. Michalska K, Szaflarska-Poplawska A, Dymek G, Kotschy M. Activation of fibrynolysis in children with chronic B or C hepatitis. Pol. Merkuriusz. Lek. 2004;17:316-20.
83. David M, Manco-Johnson M, Andrew M. Diagnosis and treatment of venous thromboembolism in children and adolescents. On behalf of the Subcommittee on Perinatal Haemostasis of the Scientific and Standardization Committee of the ISTH. Thromb. Haemost. 1995;74: 791-2.
84. Andrew M, Brooker L, Leaker M, Paes B, Weitz J. Fibrin clot lysis by thrombolytic agents is impaired in newborns due. Thrombosis & Haemostasis. 1992;68:325-30.
85. Sabovic M, Lijnen HR, Keber D, Collen D. Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators. Thromb. Haemost. 1989;62:1083-7.
86. Sabovic M, Lijnen HR, Keber D, Collen D. Correlation between progressive adsorption of plasminogen to blood clots and their sensitivity to lysis. Thromb. Haemost. 1990;64:450-4.
87. Ries M, Zenker M, Klinge J, Keuper H, Harms D. Age-related differences in a clot lysis assay after adding different plasminogen activators in a plasma milieu in vitro. J. Pediatr. Hematol. Oncol. 1995;17:260-4.
88. Ries M, Klinge J, Rauch R, Trusen B, Zenker M, Keuper H et al. In vitro fibrinolysis after adding low doses of plasminogen activators and plasmin generation with and without oxidative inactivation of plasmin inhibitors in newborns and adults. J. Pediatr. Hematol. Oncol. 1996;18:346-51.
89. Nowak-Gottl U, Auberger K, Halimeh S, Junker R, Klinge J, Kreuz WD et al. Thrombolysis in newborns and infants. Thromb. Haemost. 1999;82 Suppl 1:112-6.
90. Rimensberger PC, Humbert JR, Beghetti M. Management of preterm infants with intracardiac thrombi: use of thrombolytic agents. Paediatr. Drugs 2001;3:883-98.